Terms: = Colorectal cancer AND FBXO11, MGC44383, 80204, ENSG00000138081, Q86XK2, VIT1, UG063H01, PRMT9, FLJ12673, FBX11 AND Treatment
1 results:
1. Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line treatment in Metastatic colorectal cancer.
Kimura M; Usami E; Teramachi H; Yoshimura T
Anticancer Res; 2021 Jun; 41(6):3091-3097. PubMed ID: 34083302
[TBL] [Abstract] [Full Text] [Related]
